Crizanlizumab

Form: IV Infusion

Strength: 100 mg/10 mL (10 mg/mL)

Reference Brands: Adakveo®(EU & US)

Category: Anemia

rizanlizumab (Adakveo®) is a breakthrough biologic therapy for sickle cell disease, available for B2B pharmaceutical distribution across the US and EU markets. It is a humanized monoclonal antibody (anti-P-selectin) used to reduce the frequency of painful vaso-occlusive crises in patients with sickle cell anemia. Approved by the FDA and EMA, Crizanlizumab is supplied as a 100 mg/10 mL IV infusion, ideal for hospital and specialty clinic use. Pharma B2B partners benefit from secure supply chains, regulatory-compliant sourcing, and access to one of the most innovative therapies in hematology. Reliable distribution and market-ready packaging ensure smooth commercialization across regulated markets.